Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co. agreed to acquire Celgene Corp. in a deal valued at about $74 billion, bringing two of the top-selling cancer drugs under one roof

The companies said their pipeline includes six expected near-term product launches representing more than $15 billion in revenue potential.

Advertisements